MedTrace Logo

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

NCT04276688 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2020-04-15

No results posted yet for this study

Summary

A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir

Conditions

  • Novel Coronavirus Infection

Interventions

DRUG

Lopinavir/ritonavir

400mg/100mg twice daily for 14 days

DRUG

Ribavirin

400mg twice daily for 14 days

DRUG

Interferon Beta-1B

0.25mg subcutaneous injection alternate day for 3 days

Sponsors & Collaborators

  • Hospital Authority, Hong Kong

    collaborator OTHER_GOV

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Ivan FN Hung, MD FRCP · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-10
Primary Completion
2020-03-30
Completion
2020-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04276688 on ClinicalTrials.gov